Drug Pricing Investigation: Celgene and Bristol Myers Squibb – Revlimid (Staff Report, Committee on Oversight and Reform, U.S. House of Representatives) (2020)

Government Record · Staff of the Committee on Oversight and Reform, U.S. House of Representatives · September 30, 2020

Staff of the Committee on Oversight, 2020-09-30: House Oversight staff report finding that after the 1996 Revlimid compound patent expired in October 2019, Celgene had obtained or applied for at least 52 additional patents, and that it used ten REMS patents and sample denials to block generics.

Celgene filed for its first patent covering the active ingredient in Revlimid in 1996. This patent expired in October 2019.

p. 29

Staff of the Committee on Oversight, 2020-09-30: House Oversight staff report finding that after the 1996 Revlimid compound patent expired in October 2019, Celgene had obtained or applied for at least 52 additional patents, and that it used ten REMS patents and sample denials to block generics. Funder/conflicts: congressional staff work product (majority/Democratic staff); the report relies on Celgene internal documents obtained by subpoena and cites an I-MAK estimate that secondary patents extend the monopoly at least five years and add $45 billion in costs. Celgene's/BMS's responses are addressed in the report; the company disputed the characterization. Maker: Celgene (now Bristol Myers Squibb). Comparator: n/a. Also states Celgene paid Mylan $62 million to settle antitrust claims (p. 27). GovInfo also hosts a copy (GOVPUB-Y4_OV2-PURL-gpo182432). Study type: other.